Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study-Reference-Cited by-同舟云学术

Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study

Published:2023-06-17 Issue:12 Volume:30 Page:7876-7881
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Selby Luke V.,Clark Emma C.,Liebner David A.,Chen James L.,Tinoco Gabriel,Bashian Elizabeth,Beane Joal D.,Pollock Raphael E.,Grignol Valerie P.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-13692-0.pdf

Reference30 articles.

1. Mansfield SA, Pollock RE, Grignol VP. Surgery for abdominal well-differentiated liposarcoma. Curr Treat Options Oncol. 2018;19(1):1.

2. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416–21.

3. Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers. 2013;5(2):529–49.

4. Guan Z, Yu X, Wang H, et al. Advances in the targeted therapy of liposarcoma. OncoTargets Therapy. 2015;8:125–36.

5. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment;Experimental Hematology & Oncology;2024-08-05

2. Palbociclib;Reactions Weekly;2024-04-06

3. Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells;2024-01-05

4. Role of CDK4 as prognostic biomarker and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment;2023-11-30

5. Deciding individual treatment for primary retroperitoneal sarcoma;Expert Review of Anticancer Therapy;2023-10-25